PMID: 8581381Oct 1, 1995Paper

Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies

Journal of Hematotherapy
G C De GastB J Bast

Abstract

In extensive preclinical testing, a CD3 x CD19 bispecific antibody (BsAb) induced killing of malignant B cells by resting T cells even in an autologous situation. In a 14 day clonogenic assay using a CD19+ pre-B cell line (REH), BsAb required repeated administration together with IL-2 to achieve a 5 log kill by resting peripheral blood T cells. Intravenously administered BsAb in an intrapatient dose escalation study of 3 patients with B cell non-Hodgkin's lymphoma showed limited toxicity (WHO grade II fever and chills) due to tumor necrosis factor-alpha (TNF-alpha) release by T cells. Pharmacokinetics with 2.5 mg BsAb showed peak levels of 200-300 micrograms/ml and a t1/2 of 10.5 h. The next patient, with chronic lymphocytic leukemia (CLL), received 0.6 mg BsAb/m2 as an i.v. infusion preceded by 1 MU IL-2/m2 s.c. Improved T cell activation was noted, as indicated by an increase in IFN-gamma, IL-6, IL-8, and IL-10, in addition to high TNF-alpha increases. TNF-alpha increases were highest on the first day. Toxicity remained restricted to grade II fever and chills, observed every day after the infusion of BsAb. No clear clinical effects were seen in this chemotherapy-resistant CLL patient with a high tumor burden. If subsequent pa...Continue Reading

References

Jan 11, 1992·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·J R JacksonR B Raney
Jan 1, 1995·Leukemia & Lymphoma·G J Weiner, G C De Gast

❮ Previous
Next ❯

Citations

Jul 21, 2005·Cancer Immunology, Immunotherapy : CII·Bernd SchlerethPatrick A Baeuerle
May 14, 2005·Cancer Immunology, Immunotherapy : CII·An WillemsNico Mertens
Jan 19, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Philippe Fournier, Volker Schirrmacher
Aug 1, 2000·Immunology Today·A B van SprielJ G van De Winkel
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Oct 6, 1999·Current Opinion in Immunology·D M SegalL M Weiner
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Apr 1, 2011·Expert Opinion on Biological Therapy·Bryan D ChoiJohn H Sampson
May 26, 2015·Expert Opinion on Biological Therapy·Junnan TangKe Cheng
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Jul 5, 2005·Expert Opinion on Investigational Drugs·D L DrakemanP K Wallace
Apr 28, 2004·Trends in Biotechnology·Peter KuferPatrick A Baeuerle
Jan 18, 2006·Experimental Hematology·Lawrence G LumRandall J Lee
May 30, 2008·Advanced Drug Delivery Reviews·Robert M Sharkey, David M Goldenberg
Mar 20, 1998·International Journal of Cancer. Journal International Du Cancer·S RiedleM Zöller
Oct 1, 1996·Journal of Hematotherapy·A DwengerR Mertelsmann
Jun 9, 2019·Nature Reviews. Drug Discovery·Aran F LabrijnPaul W H I Parren
Mar 17, 2001·International Journal of Cancer. Journal International Du Cancer·O ManzkeH Bohlen
Sep 10, 2003·Current Opinion in Oncology·Jesús G Berdeja
Oct 13, 2015·Current Opinion in Hematology·Divaya Bhutani, Lawrence G Lum
Jun 25, 2020·Clinical Pharmacology and Therapeutics·Alison Betts, Piet H van der Graaf
May 28, 2020·Frontiers in Immunology·Margaux LejeuneJo Caers
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ursula ReuschLawrence G Lum
Nov 17, 1998·Bioconjugate Chemistry·Y Cao, M R Suresh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.